Comorbidities Contribute to Death Risk in Lung Cancer Later in Life

Share this content:
Cause of death in NSCLC by comorbidities such as cardiovascular disease and COPD increase with time.
Cause of death in NSCLC by comorbidities such as cardiovascular disease and COPD increase with time.

In patients with non-metastatic, non-small cell lung cancer (NSCLC), cause of death by comorbidities such as cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) increase with time, according to a study published in Annals of Oncology.

M. L. G. Janssen-Heijnen, PhD, of the VieCuri Medical Centre and fellow researchers from the Netherlands looked at data from 72,021 patients diagnosed with stage I-III NSCLC from 1989 to 2008, which they derived from the Netherlands Cancer Registry.

They matched their findings with the database of Statistics Netherlands in order to identify underlying causes of death, calculating mortality ratios and proportional causes of death during five time periods after diagnosis.

RELATED: Trametinib Shows Similar Benefit to Docetaxel in Previously Treated NSCLC

While lung cancer was the predominant cause of death in the first six years post-diagnosis at 80 to 90 percent for up to three years and 60 to 85 percent up to six years, it decreased proportionally with time, leveling off at 30 percent.

The researchers found that CVD and COPD became more important causes of death thereafter, at 34 percent and 19 percent, respectively. In particular, they were more pronounced in patients who were 60 years of age or older at diagnosis.

“Managing morbidity of these diseases remains relevant,” the authors concluded.

Reference

  1. Janssen-Heijnen, M.L.G., et al. "Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis." Annals of Oncology. doi: 10.1093/annonc/mdv061. [epub ahead of print]. February 11, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters